Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 29, 2005

View Archived Issues

MJL-1-109-2 demonstrates the involvement of CRF system in heroin dependence

Axcan reviews progress of fourth quarter

YN-968D1: A novel antiangiogenic agent

Roche describes novel, dual acting mitosis and angiogenesis inhibitor

In vivo results of APH-070 warrant its clinical evaluation

Ipsen to promote Pfizer's Artotec in France

Medivir and Jiangsu Hengrui Medicine Company extend COPD collaboration

Phase III PolyHeme trial recommended to continue

NicOx plans phase III program for HCT-3012 for osteoarthritis

Clinical results for Diamyd due in August 2006

Bosentan studies in pulmonary fibrosis show no effect on primary exercise endpoint

Varenicline, an effective and safe treatment for smoking cessation

MM-093 active, well tolerated in rheumatoid arthritis patients

Denosumab offers long-term bone improvements in postmenopausal women

EMD-336340 lowers plasma uric acid in healthy volunteers

C5a receptor antagonist ineffective in rheumatoid arthritis

Novel and potent inhibitor of c-Kit tyrosine kinase from Exelixis

Results from the ANTHEM-TIMI 32 trial of rNAPc2 presented

Hycamtin recommended for approval in Europe for relapsed SCLC

Duodopa completes market authorization in 28 European countries

Metvix approved for Bowen's disease in Europe

Results of natalizumab trials in Crohn's disease reported

U.K. approval for MT-100 for migraine

Recent patents disclose novel antiinfective agents

Steroid 5alpha-reductase inhibitors for BPH from Schering AG

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.